原发性肺淋巴上皮瘤样癌症：利用康瑞珠单抗和安罗替尼延长生存期的病例报告

IF 2.6 4区医学 Q3 CHEMISTRY, MEDICINAL

Anti-cancer agents in medicinal chemistry Pub Date : 2024-04-16 DOI:10.2174/0118715206294031240404071838

ShuangYi Lei, ShanShan Tian, SongMei Lu, Zhou Qing, JianLin Long, LuChun Li, Dan Yang

{"title":"原发性肺淋巴上皮瘤样癌症：利用康瑞珠单抗和安罗替尼延长生存期的病例报告","authors":"ShuangYi Lei, ShanShan Tian, SongMei Lu, Zhou Qing, JianLin Long, LuChun Li, Dan Yang","doi":"10.2174/0118715206294031240404071838","DOIUrl":null,"url":null,"abstract":"Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months. Case Presentation: Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib. Result: This resulted in a progression-free survival of over 26 months without significant toxic side effects. Conclusion: Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.","PeriodicalId":7934,"journal":{"name":"Anti-cancer agents in medicinal chemistry","volume":"26 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival\",\"authors\":\"ShuangYi Lei, ShanShan Tian, SongMei Lu, Zhou Qing, JianLin Long, LuChun Li, Dan Yang\",\"doi\":\"10.2174/0118715206294031240404071838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months. Case Presentation: Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib. Result: This resulted in a progression-free survival of over 26 months without significant toxic side effects. Conclusion: Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.\",\"PeriodicalId\":7934,\"journal\":{\"name\":\"Anti-cancer agents in medicinal chemistry\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-cancer agents in medicinal chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0118715206294031240404071838\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer agents in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0118715206294031240404071838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：原发性肺淋巴上皮细胞瘤样癌症（PPLELC）是一种罕见的癌症，至今尚未确立标准治疗方法。晚期肺淋巴上皮细胞瘤患者一般预后较差，总生存期为 22.7 个月。病例介绍：我们在此报告一例晚期原发性肺淋巴上皮瘤样癌患者。最初，患者接受了一线化疗（GP）和二线化疗（DP），虽然暂时缓解了病情，但造成了不同程度的骨髓抑制。当病情再次进展时，我们采用了坎瑞珠单抗联合安罗替尼的三线治疗。治疗结果无进展生存期超过26个月，且无明显毒副作用。结论我们的研究结果表明，联合使用坎瑞珠单抗和安罗替尼可以延长晚期PPLELC患者的无进展生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival

Background: Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months. Case Presentation: Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib. Result: This resulted in a progression-free survival of over 26 months without significant toxic side effects. Conclusion: Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anti-cancer agents in medicinal chemistry ONCOLOGY-CHEMISTRY, MEDICINAL

CiteScore

5.10

自引率

3.60%

发文量

323

审稿时长

4-8 weeks

期刊介绍： Formerly: Current Medicinal Chemistry - Anti-Cancer Agents. Anti-Cancer Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of anti-cancer agents. Each issue contains a series of timely in-depth reviews and guest edited issues written by leaders in the field covering a range of current topics in cancer medicinal chemistry. The journal only considers high quality research papers for publication. Anti-Cancer Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in cancer drug discovery.